AdeTherapeutics Sets New Benchmark for Fibrosis Treatment, Attracts Global Interest AdeTherapeutics, Inc. – Breaking Ground in Fibrosis Treatment – Exhibiting at BIO International Convention – April 22-25, 2013 – Chicago, Ill. 2013 BIO International Convention Booth #3831 Business Wire CHICAGO -- April 23, 2013 AdeTherapeutics, Inc., a world leader in developing patented products that reduce adhesion complications related to surgery, today announced that its innovative approach to fibrosis prevention is attracting notable physicians and partnerships worldwide. “We have patented, developed and brought into human testing a novel approach and biopharmaceutical investigational drug candidate (peptide), that when locally administered, activates the body’s internal repair mechanisms and accelerates the pace at which healing occurs,” stated Sanj Singh, CEO of AdeTherapeutics. “Our approach in dealing with fibrosis and fibrotic diseases is being explored by global leaders in the areas of gynecology, spinal peritoneal fibrosis and ophthalmology – all of which are estimated at over $30 billion.” In addition to securing partnerships in key disciplines, the company’s revolutionary approach has also attracted the most recognized professionals in the field, including recent members Dr. James Greenberg (Gynecologist at Brigham & Women’s Health), Dr. Raphael Guzman (Stanford and Basel Stem Cell) and Dr. Joanne Bargman (President, International Society of Peritoneal Dialysis). "Post-operative adhesions are a huge problem for which there is currently no good solution. AdeTherapeutic's novel approach is extremely exciting as a potential treatment," stated Dr. James Greenberg, Medical Advisory Board member specializing in Obstetrics and Gynecology with expertise in several areas. "For me, the use of a solution as opposed to a barrier or medical device is a tremendous breakthrough. I believe if this approach shows efficacy in Phase II trials it could set a new standard of care in gynecology pelvic surgeries." Progress continues globally with a joint collaboration with Royal DSM N.V. in spinal to address failed back surgery syndrome that will result in clinical trials in Europe this year. Additionally, with preclinical work about to commence with one of the leading authorities in fibrosis, Dr. Mark Sherwood at University of Florida, Gainesville, a safer anti-fibrotic may finally be available to ophthalmologists. AdeTherapeutics will tout its fibrosis prevention benchmark at the 2013 BIO International Convention in the Canada Café in the Saskatchewan Biosciences Booth #3831. CEO Sanj Singh is presenting at the BIOTECanada showcase series on Wednesday, April 24^th at 1:30pm. For more information, visit http://www.adetherapeutics.com/. All trademarks recognized. Contact: AdeTherapeutics, Inc. Sanj Singh, +1-306-261-5189 firstname.lastname@example.org or BroadPR, Inc. Tracy Wemett, +1-617-868-5031 email@example.com
AdeTherapeutics Sets New Benchmark for Fibrosis Treatment, Attracts Global Interest
Press spacebar to pause and continue. Press esc to stop.